
Lexicon Pharmaceuticals (LXRX) Stock Forecast & Price Target
Lexicon Pharmaceuticals (LXRX) Analyst Ratings
Bulls say
Lexicon Pharmaceuticals Inc. recently achieved favorable topline results from the Phase 2b PROGRESS clinical trial for its drug candidate LX9211, which targets diabetic peripheral neuropathic pain (DPNP), thereby enhancing confidence in its therapeutic potential. The positive clinical outcomes, coupled with robust partnership interest and a significant addressable market of approximately 9 million diagnosed cases of DPNP in the U.S., indicate strong prospects for revenue generation. In addition, the company’s strategy to expand market penetration for existing treatments while introducing earlier-stage assets, such as LX9851 for obesity and cardiometabolic conditions, further supports a positive outlook for its stock performance.
Bears say
Lexicon Pharmaceuticals faces a negative outlook primarily due to disappointing clinical trial results, particularly with its 20 mg dose of RELIEF DPN-1, which failed to achieve statistical significance compared to placebo despite some positive data observed at different dose levels. The potential for future setbacks looms large given the risks associated with inconclusive trial outcomes and the company’s challenges in securing sufficient funding to advance its drug development pipeline. Additionally, concerns regarding tolerability issues and high dropout rates further contribute to skepticism around the company's ability to generate value from its drug candidates.
This aggregate rating is based on analysts' research of Lexicon Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Lexicon Pharmaceuticals (LXRX) Analyst Forecast & Price Prediction
Start investing in Lexicon Pharmaceuticals (LXRX)
Order type
Buy in
Order amount
Est. shares
0 shares